GlassScriptPhysician profile
Sandra Zila-Eivins
NPI 1972509909
$2,105.71
in general payments reported to CMS, 2019-2025
24 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $205 · 2021: $177 · 2022: $238 · 2023: $334 · 2024: $547 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.28 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $309.29 | 2019-2022 | |
| Abbvie INC. | $308.21 | 2022-2025 | Botox |
| Janssen Biotech, INC. | $231.63 | 2019-2024 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $227.42 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $221.96 | 2019-2025 | |
| Galderma Laboratories, L.P. | $139.30 | 2019-2023 | |
| Ucb, INC. | $109.02 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $80.42 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $76.41 | 2021-2024 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $70.55 | 2023-2024 | Ilumya |
| Novartis Pharmaceuticals Corporation | $49.11 | 2024-2025 | |
| Incyte Corporation | $47.86 | 2022-2023 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $24.37 | 2024 | |
| Dermavant Sciences, INC. | $22.41 | 2023 | Vtama |
| Organogenesis INC. | $21.36 | 2023 | Puraply |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $20.32 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $20.22 | 2020 | |
| Pfizer INC. | $20.18 | 2024 | |
| Sandoz INC. | $19.95 | 2024 | Hyrimoz |
| Leo Pharma INC. | $19.05 | 2022 | |
| Merz North America, INC. | $18.32 | 2020 | |
| Journey Medical Corporation | $18.19 | 2022 | |
| Sensus Healthcare, INC. | $8.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Zila-Eivins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.